• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SCHEDULE 13G filed by ARS Pharmaceuticals Inc.

    3/24/26 4:18:45 PM ET
    $SPRY
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $SPRY alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    ARS Pharmaceuticals, Inc.

    (Name of Issuer)


    Common Stock, par value $0.0001 per share

    (Title of Class of Securities)




    82835W108

    (CUSIP Number)
    03/17/2026

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox not checked   Rule 13d-1(b)
    Checkbox checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)




    schemaVersion:


    SCHEDULE 13G

    CUSIP Number(s):
    82835W108


    1Names of Reporting Persons

    Millennium Management LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    5,391,440.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    5,391,440.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    5,391,440.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    5.4 %
    12Type of Reporting Person (See Instructions)

    OO


    SCHEDULE 13G

    CUSIP Number(s):
    82835W108


    1Names of Reporting Persons

    Millennium Group Management LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    5,391,440.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    5,391,440.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    5,391,440.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    5.4 %
    12Type of Reporting Person (See Instructions)

    OO


    SCHEDULE 13G

    CUSIP Number(s):
    82835W108


    1Names of Reporting Persons

    Israel A. Englander
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    5,391,440.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    5,391,440.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    5,391,440.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    5.4 %
    12Type of Reporting Person (See Instructions)

    IN


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    ARS Pharmaceuticals, Inc.
    (b)Address of issuer's principal executive offices:

    11682 El Camino Real, Suite 300, San Diego, California 92130
    Item 2. 
    (a)Name of person filing:

    Millennium Management LLC Millennium Group Management LLC Israel A. Englander
    (b)Address or principal business office or, if none, residence:

    Millennium Management LLC 399 Park Avenue New York, New York 10022 Millennium Group Management LLC 399 Park Avenue New York, New York 10022 Israel A. Englander c/o Millennium Management LLC 399 Park Avenue New York, New York 10022
    (c)Citizenship:

    Millennium Management LLC - Delaware Millennium Group Management LLC - Delaware Israel A. Englander - United States
    (d)Title of class of securities:

    Common Stock, par value $0.0001 per share
    (e)CUSIP Number(s):

    82835W108
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    See response to Item 9 on each cover page.
    (b)Percent of class:

    See response to Item 11 on each cover page.
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    See response to Item 5 on each cover page.

     (ii) Shared power to vote or to direct the vote:

    See response to Item 6 on each cover page.

     (iii) Sole power to dispose or to direct the disposition of:

    See response to Item 7 on each cover page.

     (iv) Shared power to dispose or to direct the disposition of:

    See response to Item 8 on each cover page. The securities disclosed herein as potentially beneficially owned by Millennium Management LLC, Millennium Group Management LLC and Mr. Englander are held by entities subject to voting control and investment discretion by Millennium Management LLC and/or other investment managers that may be controlled by Millennium Group Management LLC (the managing member of Millennium Management LLC) and Mr. Englander (the sole voting trustee of the managing member of Millennium Group Management LLC). The foregoing should not be construed in and of itself as an admission by Millennium Management LLC, Millennium Group Management LLC or Mr. Englander as to beneficial ownership of the securities held by such entities.

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Not Applicable
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    If a group has filed this schedule pursuant to §240.13d-1(b)(1)(ii)(K), so indicate under Item 3(k) and attach an exhibit stating the identity and Item 3 classification of each member of the group. If a group has filed this schedule pursuant to §240.13d-1(c) or §240.13d-1(d), attach an exhibit stating the identity of each member of the group.


    See Exhibit I
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Millennium Management LLC
     
    Signature:/s/ Gil Raviv
    Name/Title:Gil Raviv, Global General Counsel
    Date:03/23/2026
     
    Millennium Group Management LLC
     
    Signature:/s/ Gil Raviv
    Name/Title:Gil Raviv, Global General Counsel
    Date:03/23/2026
     
    Israel A. Englander
     
    Signature:/s/ Israel A. Englander
    Name/Title:Israel A. Englander
    Date:03/23/2026
    Exhibit Information

    Exhibit I: Joint Filing Agreement, dated as of March 23, 2026, by and among Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander.

    Get the next $SPRY alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $SPRY

    DatePrice TargetRatingAnalyst
    11/4/2025$30.00Buy
    Roth Capital
    9/4/2025$40.00Buy
    Roth Capital
    3/7/2025$30.00Sector Outperform
    Scotiabank
    2/10/2025$40.00Outperform
    Oppenheimer
    8/20/2024Overweight
    Cantor Fitzgerald
    8/13/2024$18.00 → $22.00Outperform → Strong Buy
    Raymond James
    8/12/2024$19.00 → $20.00Outperform
    Leerink Partners
    7/25/2024$18.00Outperform
    Raymond James
    More analyst ratings

    $SPRY
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Roth Capital resumed coverage on ARS Pharmaceuticals with a new price target

    Roth Capital resumed coverage of ARS Pharmaceuticals with a rating of Buy and set a new price target of $30.00

    11/4/25 8:07:28 AM ET
    $SPRY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Roth Capital initiated coverage on ARS Pharmaceuticals with a new price target

    Roth Capital initiated coverage of ARS Pharmaceuticals with a rating of Buy and set a new price target of $40.00

    9/4/25 7:57:34 AM ET
    $SPRY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Scotiabank initiated coverage on ARS Pharmaceuticals with a new price target

    Scotiabank initiated coverage of ARS Pharmaceuticals with a rating of Sector Outperform and set a new price target of $30.00

    3/7/25 8:14:43 AM ET
    $SPRY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SPRY
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Ra Capital Management, L.P. bought $13,289,410 worth of shares (1,401,299 units at $9.48) (SEC Form 4)

    4 - ARS Pharmaceuticals, Inc. (0001671858) (Issuer)

    3/27/24 7:37:52 PM ET
    $SPRY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SPRY
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    ARS Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Updates on neffy® (epinephrine nasal spray) Commercialization

    neffy delivers $72.2 million of U.S. net product revenue in first full year Intranasal epinephrine platform advances with Phase 2b CSU data expected mid-2026 Strong balance sheet of $245.0 million in cash, cash equivalents and short-term investments supports operating plan through anticipated cash-flow break-even  Conference call to be held today, March 9, 2026, at 5:30 a.m. PT / 8:30 a.m. ET SAN DIEGO, March 09, 2026 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (NASDAQ:SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect patients from allergic reactions that could lead to anaphylaxis, today announced financial results for t

    3/9/26 6:00:00 AM ET
    $SPRY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ARS Pharmaceuticals Announces Conference Call and Webcast for its Fourth Quarter and Full Year 2025 Financial Results and Participation at Upcoming Conferences

    SAN DIEGO, Feb. 23, 2026 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (NASDAQ:SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect patients from allergic reactions that could lead to anaphylaxis, today announced the company will host a conference call and webcast on Monday, March 9, 2026 at 5:30 a.m. PT / 8:30 a.m. ET to discuss its fourth quarter and full year 2025 financial results and business highlights. Dial-in information for conference participants may be obtained by registering for the event. In addition, ARS Pharma Management will be participating at several upcoming investor conferences: 10th Annual Oppenheimer Emer

    2/23/26 8:00:00 AM ET
    $SPRY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ARS Pharmaceuticals to Showcase Scientific Innovation and Robust Clinical Data on neffy® (epinephrine nasal spray) at 2026 American Academy of Allergy, Asthma and Immunology (AAAAI) Annual Scientific Meeting

    -Five poster presentations highlight clinical advancement of neffy, real-world usability and advantages of needle-free epinephrine delivery -Longer shelf life of nasal epinephrine compared with epinephrine auto-injectors translates into a more affordable, value-based price -When factoring in patients' dislike of needle-based administration, the value of a nasal option increased by more than 25% SAN DIEGO, Feb. 10, 2026 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (NASDAQ:SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect patients from severe allergic reactions that could lead to anaphylaxis, announced today that five poste

    2/10/26 8:00:00 AM ET
    $SPRY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SPRY
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Chief Financial Officer Scott Kathleen D.

    4 - ARS Pharmaceuticals, Inc. (0001671858) (Issuer)

    1/5/26 4:27:42 PM ET
    $SPRY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Chief Commercial Officer Karas Eric

    4 - ARS Pharmaceuticals, Inc. (0001671858) (Issuer)

    1/5/26 4:26:31 PM ET
    $SPRY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Chief Legal Officer Fitzpatrick Alexander A

    4 - ARS Pharmaceuticals, Inc. (0001671858) (Issuer)

    1/5/26 4:25:06 PM ET
    $SPRY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SPRY
    SEC Filings

    View All

    SEC Form SCHEDULE 13G filed by ARS Pharmaceuticals Inc.

    SCHEDULE 13G - ARS Pharmaceuticals, Inc. (0001671858) (Subject)

    3/24/26 4:18:45 PM ET
    $SPRY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-8 filed by ARS Pharmaceuticals Inc.

    S-8 - ARS Pharmaceuticals, Inc. (0001671858) (Filer)

    3/9/26 4:01:29 PM ET
    $SPRY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-K filed by ARS Pharmaceuticals Inc.

    10-K - ARS Pharmaceuticals, Inc. (0001671858) (Filer)

    3/9/26 6:07:39 AM ET
    $SPRY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SPRY
    Leadership Updates

    Live Leadership Updates

    View All

    ADARx Pharmaceuticals Appoints Industry Veteran, Laura Shawver, Ph.D., as Board Chair

    – Accomplished biopharma executive and entrepreneur brings a 25-year track record of upscaling valuable companies and realizing the potential of their innovations – SAN DIEGO, Sept. 17, 2025 (GLOBE NEWSWIRE) -- ADARx Pharmaceuticals, Inc. (ADARx), a late-stage clinical biotechnology company developing next-generation RNA therapeutics, today announced the appointment of Laura Shawver, Ph.D., as Chair of its Board of Directors. "We are honored to welcome Dr. Shawver to our Board. Laura's outstanding track record of driving strategic growth and developing innovative therapies comes at a pivotal time as we scale to advance our pipeline and expand the impact of our next-generation

    9/17/25 9:00:00 AM ET
    $SPRY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ARS Pharmaceuticals Announces neffy® (Epinephrine Nasal Spray) is available on Express Scripts Commercial National Formularies

    Inclusion of neffy on Express Scripts commercial formularies was effective November 22, 2024 and expands access to patients and caregivers managing Type 1 Allergic Reactions SAN DIEGO, Dec. 19, 2024 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (NASDAQ:SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect themselves from allergic reactions that could lead to anaphylaxis, announced today that Express Scripts, the pharmacy benefits business of Evernorth Health Services, has added neffy® (epinephrine nasal spray) to its Commercial national formularies. This decision makes neffy broadly available to millions of their commercially insured

    12/19/24 5:25:09 PM ET
    $SPRY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SPRY
    Financials

    Live finance-specific insights

    View All

    ARS Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Updates on neffy® (epinephrine nasal spray) Commercialization

    neffy delivers $72.2 million of U.S. net product revenue in first full year Intranasal epinephrine platform advances with Phase 2b CSU data expected mid-2026 Strong balance sheet of $245.0 million in cash, cash equivalents and short-term investments supports operating plan through anticipated cash-flow break-even  Conference call to be held today, March 9, 2026, at 5:30 a.m. PT / 8:30 a.m. ET SAN DIEGO, March 09, 2026 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (NASDAQ:SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect patients from allergic reactions that could lead to anaphylaxis, today announced financial results for t

    3/9/26 6:00:00 AM ET
    $SPRY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ARS Pharmaceuticals Announces Conference Call and Webcast for its Fourth Quarter and Full Year 2025 Financial Results and Participation at Upcoming Conferences

    SAN DIEGO, Feb. 23, 2026 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (NASDAQ:SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect patients from allergic reactions that could lead to anaphylaxis, today announced the company will host a conference call and webcast on Monday, March 9, 2026 at 5:30 a.m. PT / 8:30 a.m. ET to discuss its fourth quarter and full year 2025 financial results and business highlights. Dial-in information for conference participants may be obtained by registering for the event. In addition, ARS Pharma Management will be participating at several upcoming investor conferences: 10th Annual Oppenheimer Emer

    2/23/26 8:00:00 AM ET
    $SPRY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ARS Pharmaceuticals Reports Third Quarter 2025 Financial Results and Highlights for neffy® (epinephrine nasal spray)

    $32.5 million in revenue, including $31.3 million in neffy U.S. net product revenue in third quarter of 2025 Continued U.S. product growth driven by direct-to-consumer (DTC) investments and real-world evidence, expected to accelerate with seamless prescribing experience Strong balance sheet of $288.2 million cash, cash equivalents and short-term investments anticipated to fund operations through cash-flow break-even Conference call to be held today, November 10, 2025, at 5:30 a.m. PT / 8:30 a.m. ET  SAN DIEGO, Nov. 10, 2025 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (NASDAQ:SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better pro

    11/10/25 6:00:00 AM ET
    $SPRY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SPRY
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by ARS Pharmaceuticals Inc.

    SC 13D/A - ARS Pharmaceuticals, Inc. (0001671858) (Subject)

    6/17/24 8:47:57 PM ET
    $SPRY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by ARS Pharmaceuticals Inc.

    SC 13D/A - ARS Pharmaceuticals, Inc. (0001671858) (Subject)

    6/11/24 7:18:55 PM ET
    $SPRY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D/A filed by ARS Pharmaceuticals Inc. (Amendment)

    SC 13D/A - ARS Pharmaceuticals, Inc. (0001671858) (Subject)

    3/29/24 4:14:13 PM ET
    $SPRY
    Biotechnology: Pharmaceutical Preparations
    Health Care